These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35400600)

  • 21. Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.
    Tiotiu A; Ioan I; Billon Y
    Pulm Pharmacol Ther; 2023 Oct; 82():102248. PubMed ID: 37562640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Boutin S; Wielpütz MO; Joachim C; Frey DL; Wege S; Sommerburg O; Kauczor HU; Stahl M; Dalpke AH; Mall MA
    Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Lynch DA; Taylor-Cousar JL
    Ann Am Thorac Soc; 2022 Jan; 19(1):12-19. PubMed ID: 34436985
    [No Abstract]   [Full Text] [Related]  

  • 25. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Schaupp L; Addante A; Völler M; Fentker K; Kuppe A; Bardua M; Duerr J; Piehler L; Röhmel J; Thee S; Kirchner M; Ziehm M; Lauster D; Haag R; Gradzielski M; Stahl M; Mertins P; Boutin S; Graeber SY; Mall MA
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
    Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
    J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Arslan M; Bahadir Z; Basiaga ML; Chalmers SJ; Demirel N
    J Cyst Fibros; 2023 Nov; 22(6):1120-1122. PubMed ID: 37709627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
    Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
    J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
    Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS
    Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis.
    Atteih SE; Armbruster CR; Hilliam Y; Rapsinski GJ; Bhusal JK; Krainz LL; Gaston JR; DuPont M; Zemke AC; Alcorn JF; Moore JA; Cooper VS; Lee SE; Forno E; Bomberger JM
    Pediatr Pulmonol; 2024 May; 59(5):1266-1273. PubMed ID: 38353361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.
    Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M
    BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.
    Caley LR; Jarosz-Griffiths HH; Smith L; Gale L; Barrett J; Kinsey L; Davey V; Nash M; Jones AM; Whitehouse JL; Shimmin D; Floto RA; White H; Peckham DG
    J Cyst Fibros; 2023 Nov; 22(6):1002-1009. PubMed ID: 37422432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.
    McCoy KS; Blind J; Johnson T; Olson P; Raterman L; Bai S; Eisner M; Sheikh SI; Druhan S; Young C; Pasley K
    Pediatr Pulmonol; 2023 Apr; 58(4):1178-1184. PubMed ID: 36650567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.
    Sheikh S; Britt RD; Ryan-Wenger NA; Khan AQ; Lewis BW; Gushue C; Ozuna H; Jaganathan D; McCoy K; Kopp BT
    Pediatr Pulmonol; 2023 Mar; 58(3):825-833. PubMed ID: 36444736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
    Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F
    J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Ramakrishnan VR; Taylor-Cousar JL
    J Cyst Fibros; 2022 Mar; 21(2):e141-e147. PubMed ID: 34598881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.